We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
- Authors
Komizo, Takashi; Ono, Takashi; Yagi, Akiko; Miyata, Kazunori; Aihara, Makoto
- Abstract
Purpose: The present study aimed to investigate the effectiveness of adjunctive therapy involving the Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitor ripasudil in lowering intraocular pressure (IOP) in patients with different subtypes of glaucoma, on the basis of the time of IOP measurementStudy design: Retrospective studyMethods: In total, 58 patients who underwent adjunctive therapy with ripasudil at a single institution were included. They were classified into a primary open-angle glaucoma (POAG) group, an exfoliation glaucoma (XFG) group, and a secondary glaucoma associated with uveitis, or steroid glaucoma (SG), group. The average IOPs within 6 months before (pre-IOP) and after (post-IOP) the addition of ripasudil were compared among the 3 groups. The IOP values of the morning-visit and afternoon-visit groups were also compared to reflect the peak effectiveness of ripasudil.Results: The IOP reductions in the POAG (n = 38), XFG (n = 6), and SG (n = 14) groups were −1.1, +0.5, and +0.5 mmHg, respectively. Significant reductions in IOP were observed in the POAG group (P = .014). The IOP reductions in the POAG morning-visit and afternoon-visit groups were −1.9 and +0.5 mmHg, respectively. IOP was significantly reduced in the morning-visit POAG group after treatment with ripasudil (P = .002). The IOP values measured during morning visits were lower than those measured during afternoon visits (IOP reduction: −1.3 mmHg; P = .011).Conclusions: The findings of the present study indicate that ripasudil is effective as an adjunctive therapy for lowering IOP in patients with POAG; these reductions are more significant when measured closer to the time of peak effectiveness.
- Subjects
OPEN-angle glaucoma; PROTEIN kinases; BIMATOPROST; KINASE inhibitors; GLAUCOMA; INTRAOCULAR pressure
- Publication
Japanese Journal of Ophthalmology, 2019, Vol 63, Issue 1, p40
- ISSN
0021-5155
- Publication type
Article
- DOI
10.1007/s10384-018-0635-0